These differences were also found after fluoxetine treatment in the corticosterone-induced chronic depression model, with concentrations of these compounds significantly decreased in mutant mice brain compared to WT mice and, conversely, increased in the plasma of mutants, emphasizing the contribution of OCT2-mediated transport in modulating brain levels of these metabolites. The gene discussed is SLC22A2; the disease is depressive symptom measurement.